HBM HLDGS LTD DL-000025 (6XY) - Net Assets
Based on the latest financial reports, HBM HLDGS LTD DL-000025 (6XY) has net assets worth €367.11 Million EUR (≈ $429.19 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€500.26 Million ≈ $584.85 Million USD) and total liabilities (€133.14 Million ≈ $155.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of HBM HLDGS LTD DL-000025 for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €367.11 Million |
| % of Total Assets | 73.38% |
| Annual Growth Rate | 13.28% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 94.1 |
HBM HLDGS LTD DL-000025 - Net Assets Trend (2021–2025)
This chart illustrates how HBM HLDGS LTD DL-000025's net assets have evolved over time, based on quarterly financial data. Also explore total assets of HBM HLDGS LTD DL-000025 for the complete picture of this company's asset base.
Annual Net Assets for HBM HLDGS LTD DL-000025 (2021–2025)
The table below shows the annual net assets of HBM HLDGS LTD DL-000025 from 2021 to 2025. For live valuation and market cap data, see HBM HLDGS LTD DL-000025 market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €367.11 Million ≈ $429.19 Million |
+195.93% |
| 2024-12-31 | €124.05 Million ≈ $145.03 Million |
+3.70% |
| 2023-12-31 | €119.63 Million ≈ $139.86 Million |
+29.33% |
| 2022-12-31 | €92.50 Million ≈ $108.14 Million |
-58.50% |
| 2021-12-31 | €222.91 Million ≈ $260.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HBM HLDGS LTD DL-000025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 61719300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €984.32 Million | 268.12% |
| Total Equity | €367.12 Million | 100.00% |
HBM HLDGS LTD DL-000025 Competitors by Market Cap
The table below lists competitors of HBM HLDGS LTD DL-000025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Generation Development Group Ltd
AU:GDG
|
$1.17 Billion |
|
Shanghai Chengdi Constr Co
SHG:603887
|
$1.17 Billion |
|
Hapvida Participações e Investimentos S.A.
SA:HAPV3
|
$1.17 Billion |
|
Bonheur
OL:BONHR
|
$1.17 Billion |
|
ASA Gold and Precious Metals Ltd
NYSE:ASA
|
$1.17 Billion |
|
Topscore Fashion
SHG:603608
|
$1.17 Billion |
|
Hyosung TNC Corp
KO:298020
|
$1.17 Billion |
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
$1.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HBM HLDGS LTD DL-000025's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 124,447,000 to 367,125,000, a change of 242,678,000 (195.0%).
- Net income of 91,333,000 contributed positively to equity growth.
- Share repurchases of 25,082,000 reduced equity.
- New share issuances of 172,096,000 increased equity.
- Other factors increased equity by 4,331,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €91.33 Million | +24.88% |
| Share Repurchases | €25.08 Million | -6.83% |
| Share Issuances | €172.10 Million | +46.88% |
| Other Changes | €4.33 Million | +1.18% |
| Total Change | €- | 195.01% |
Book Value vs Market Value Analysis
This analysis compares HBM HLDGS LTD DL-000025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.37x to 2.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.30 | €1.31 | x |
| 2022-12-31 | €0.13 | €1.31 | x |
| 2023-12-31 | €0.16 | €1.31 | x |
| 2024-12-31 | €0.17 | €1.31 | x |
| 2025-12-31 | €0.44 | €1.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HBM HLDGS LTD DL-000025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.88%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 57.81%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.36x
- Recent ROE (24.88%) is above the historical average (-32.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -61.73% | -3198.17% | 0.02x | 1.27x | €-160.10 Million |
| 2022 | -147.83% | -337.49% | 0.18x | 2.50x | €-146.50 Million |
| 2023 | 19.00% | 25.47% | 0.39x | 1.90x | €10.80 Million |
| 2024 | 2.23% | 7.29% | 0.18x | 1.73x | €-9.67 Million |
| 2025 | 24.88% | 57.81% | 0.32x | 1.36x | €54.62 Million |
Industry Comparison
This section compares HBM HLDGS LTD DL-000025's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $353,958,690
- Average return on equity (ROE) among peers: -34.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HBM HLDGS LTD DL-000025 (6XY) | €367.11 Million | -61.73% | 0.36x | $1.17 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more